Taken together, we conclude that the atheroprotective effect of Maxadilan is mainly downstream of cholesterol-induced inflammation, such as induction of TNF-α and IL-1β and, in addition, may involve activation of vasoprotective signaling, reduction of apoptosis, and hypertriglyceridemia. The gene discussed is IL1B; the disease is hypertriglyceridemia.